Search Results - "Guirchoun, Patrick"

An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International by Müller, Roman-Ulrich, Lianne Messchendorp, A., Birn, Henrik, Capasso, Giovambattista, Cornec-Le Gall, Emilie, Devuyst, Olivier, Eerde, Albertien van, Guirchoun, Patrick, Harris, Tess, Hoorn, Ewout J., Knoers, Nine V.A.M., Korst, Uwe, Mekahli, Djalila, Le Meur, Yannick, Nijenhuis, Tom, Ong, Albert C.M., Sayer, John A., Schaefer, Franz, Servais, Aude, Tesar, Vladimir, Torra, Roser, Gansevoort, Stephen B. Walsh and Ron T.

Get full text

An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International by Müller, Roman-Ulrich, Messchendorp, A Lianne, Birn, Henrik, Capasso, Giovambattista, Cornec-Le Gall, Emilie, Devuyst, Olivier, van Eerde, Albertien, Guirchoun, Patrick, Harris, Tess, Hoorn, Ewout J, Knoers, Nine V A M, Korst, Uwe, Mekahli, Djalila, Le Meur, Yannick, Nijenhuis, Tom, Ong, Albert C M, Sayer, John A, Schaefer, Franz, Servais, Aude, Tesar, Vladimir, Torra, Roser, Walsh, Stephen B, Gansevoort, Ron T

“…ABSTRACT Approval of the vasopressin V2 receptor antagonist tolvaptan—based on the landmark TEMPO 3:4 trial—marked a transformation in the management of…”
Get full text